Ottawa Heart Institute Research Corporation

ottawaheart.ca

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

180

Active

59

Phase 3

29

Total enrollment

85,071

Pipeline matrix

Showing 20 of 20 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Normal saline3
Milrinone2
Dobutamine2
Varenicline2
Genotyping guided therapy for anti-platelet management1
Nicotine Replacement Therapy1
Cytisine2
Dexmedetomidine2
Clopidogrel4
aspirin2
Canagliflozin1
Midodrine Oral1
Semaglutide1
Nicotine replacement1
Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]1
Prednisone or Prednisolone1
Methotrexate1
Dapagliflozin1
Dapagliflozin 10mg Tab1
Rb-82 Radioisotope1

Next readouts

  • 2026-07
  • 2026-12
  • 2026-12
  • 2026-12
  • 2026-12-31
  • 2026-12-31
  • 2027-03
  • 2027-04-30
  • 2027-05-08
  • 2027-06

Top conditions

  • Coronary Artery Disease31
  • Atrial Fibrillation19
  • Heart Failure15
  • Acute Coronary Syndrome10
  • Cardiovascular Diseases10
  • Coronary Heart Disease9
  • Smoking Cessation8
  • Myocardial Infarction5

Frequently asked questions about Ottawa Heart Institute Research Corporation

How many clinical trials does Ottawa Heart Institute Research Corporation have on ClinicalTrials.gov?
Ottawa Heart Institute Research Corporation is listed as the lead sponsor on 180 clinical trials in ClinicalTrials.gov, 59 of which are currently active (recruiting, enrolling, or ongoing).
How many of Ottawa Heart Institute Research Corporation's trials are in Phase 3?
29 of Ottawa Heart Institute Research Corporation's trials are in Phase 3, spread across 20 active drug programs.
What therapeutic areas does Ottawa Heart Institute Research Corporation focus on?
Ottawa Heart Institute Research Corporation's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Atrial Fibrillation, Heart Failure, Acute Coronary Syndrome, Cardiovascular Diseases.
When are Ottawa Heart Institute Research Corporation's next clinical trial readouts?
Ottawa Heart Institute Research Corporation has 10 upcoming primary-completion readouts tracked here; the soonest is “Semaglutide for Smoking Cessation in Patients With Diabetes”, expected around 2026-07.